Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Renal Cell 2Advanced Malignant Solid Neoplasm 2Vaginal Neoplasms 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pinealoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Myelodysplastic Syndromes 1Metastatic Pancreatic Adenocarcinoma 1Meningeal Carcinomatosis 1Melanoma 1

Interventions

adavosertib 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Pancreatic Adenocarcinoma × adavosertib × Clear all
NCT02194829 2023-04-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Completed
8 enrolled 9 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡